Hunter Syndrome Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight

Hunter Syndrome Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight

“Hunter Syndrome Market Insight Report”
DelveInsight’s “Hunter Syndrome Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on Hunter Syndrome Market Insights, Epidemiology and Market Forecast-2030  

The Hunter Syndrome market report provides current treatment practices, emerging drugs, Hunter Syndrome market share of the individual therapies, current and forecasted Hunter Syndrome Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hunter Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Key benefits of the report
1. Hunter Syndrome market report covers a descriptive overview and comprehensive insight of the Hunter Syndrome epidemiology and Hunter Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 
2. Hunter Syndrome market report provides insights on the current and emerging therapies.
3. Hunter Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.  
4. Hunter Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hunter Syndrome market.

“Hunter syndrome occurs almost exclusively in males”

Hunter Syndrome, also known as Mucopolysaccharidosis type II (MPS II), I2S deficiency and Iduronate 2-sulfatase deficiency. It is an inherited disorder of carbohydrate metabolism that occurs almost exclusively in males. MPS II is caused by mutations in the IDS gene and is inherited in an X-linked manner. Females are generally unaffected carriers of this condition. As per National MPS Society, Hunter syndrome takes its name from Charles Hunter, the professor of medicine in Manitoba, Canada, who first described two brothers with the disease in 1917. MPS II has a wide range of symptoms that vary in severity and can be managed and treated with enzyme replacement therapies. There is no cure for MPS II and it affects 1 in 100,000 to 1 in 170,000 primarily males. It is characterized by distinctive facial features, a large head, hydrocephalus, enlargement of the liver and spleen (hepatosplenomegaly), umbilical or inguinal hernia, and hearing loss. Individuals with this condition may additionally have joint deformities and heart abnormalities involving the valves.

Request for sample pages here -> https://www.delveinsight.com/sample-request/hunter-syndrome-market

Drugs covered

  1. 1.           JR-141
  2. 2.           GC1111B or Hunterase
  3. 3.          RGX-121

And many others

The key players in Hunter Syndrome market are:

  1. JCR Pharmaceuticals
  2. Green Cross Corporation
  3. Regenxbio Inc.

And many others

Table of contents

1. Report Introduction

2. Hunter Syndrome Market Overview at a Glance

3. Hunter syndrome Disease Background and Overview

4. Hunter syndrome Epidemiology and Patient Population

5. Epidemiology of Hunter syndrome by Countries (2017–2030)

5.1. United States- Epidemiology (2017–2030)

5.2. EU-5 – Epidemiology (2017–2030)

5.3. Germany-Epidemiology (2017–2030)

5.4. France-Epidemiology (2017–2030)

5.5. Italy-Epidemiology (2017–2030)

 5.6. Spain-Epidemiology (2017–2030)

5.7. United Kingdom-Epidemiology (2017–2030)

5.8. Japan-Epidemiology (2017–2030)

6. Treatments & Medical Practices

7. Hunter syndrome Marketed Products

7.1. Elaprase: Shire

8. Emerging Therapies

8.1. Key Cross Competition

8.2. JR-141: JCR Pharmaceuticals

8.3. GC1111B or Hunterase: Green Cross Corporation

8.4. RGX-121: Regenxbio Inc.

9. Hunter syndrome Market Size

10. 7MM: Country-Wise Market Analysis

10.1. United States Market Size

10.2. Germany Market Size

10.3. France Market Size

 10.4. Italy Market Size

10.5. Spain Market Size

10.6. United Kingdom Market Size

10.7. Japan Market Size

11. Market Drivers

12. Market Barriers

13. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

Request for sample pages here ->https://www.delveinsight.com/sample-request/hunter-syndrome-market

Related Reports:

DelveInsight’s Hunter Syndrome – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hunter Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hunter Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hunter Syndrome market.

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/